[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"warts\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:warts":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,49,76,107,130,155,181,203,226,250,270,292],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100130517","phase-1-a-phase-i-study-of-mozobil-in-the-treatment-of-patients-with-whims-100130517",false,"NCT00967785","A Phase I Study of Mozobil in the Treatment of Patients With WHIMS","A Phase I Study of MozobilTM in the Treatment of Patients With WHIMS","* INCLUSION CRITERIA:\n\nAll of the following inclusion criteria must be met for a subject to be enrolled in this study:\n\n* Clinical diagnosis of WHIMS and documented severe infection\n* Must be greater than or equal to 18 and less than or equal to 75 years of age\n* Willingness to interrupt medications to raise the white count (WBC) such as G-CSF or GM-CSF for at least 2 days before and while on the study drug\n* Must not be pregnant or breastfeeding\n* Must have a personal physician\n* Must be willing to provide blood, plasma, serum, and DNA samples for storage\n* Subjects must agree not to become pregnant or to impregnate a female. If of childbearing potential, must agree to consistently use two types of contraception throughout study participation. Acceptable forms of contraception include the following:\n\n  1. Condoms, male or female, with or without a spermicide\n  2. Diaphragm or cervical cap with spermicide\n  3. Intrauterine device\n  4. Contraceptive pills or patch, Norplant, Depo-Provera or other FDA-approved contraceptive method\n  5. Male partner has previously undergone a vasectomy for which there is documentation of aspermatogenic sterility\n\nEXCLUSION CRITERIA:\n\nIf any of the following exclusion criteria are met, a subject will not be enrolled in this study:\n\n* Absence of a diagnosis of WHIMS\n* Patient is less than 18 years old\n* Absence of a documented history of severe infection\n* Neutropenia due to maturation defects in the myeloid lineage or that the PI feels is unlikely to benefit from this medication\n* Pregnant women or breastfeeding\n* History of serious cardiac arrhythmia or cardiac defects that make such more likely\n* Renal failure (calculated creatinine clearance \\[CrCl\\] \\\u003C15 mL\u002Fmin or requiring dialysis)\n* Signs or symptoms of active microbial infection at the time of study entry.\n* Any condition that, in the investigator s opinion, places the patient at undue risk by participating in the study\n* Unwillingness to undergo testing or procedures associated with this protocol","ALL","18 Years","75 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","Background:\n\n* WHIMS (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome) is caused by various genetic changes that increase the activity of the chemokine receptor, CXCR4. Excessive function of this receptor causes mature neutrophils (part of the white blood cells) to be retained within the bone marrow rather than being released to the blood and is one of the causes of severe inherited neutropenia (low white blood counts). In neutropenia, the body is less able to fight off infection. Patients with WHIMS usually are at risk for skin, soft tissue, sinus, and lung infections, which can result in loss of hearing, teeth, and lung function.\n* Current treatment for WHIMS consists of regular injections of a white blood cell growth stimulating medication called granulocyte colony stimulating factor (G-CSF), and supplemental immunoglobulin (antibody). These therapies are expensive, nonspecific, have significant side effects and toxicities, and do not fully correct all problems, especially warts and cancers related to human papillomavirus (HPV).\n* A drug called Mozobil has been approved for use in combination with G-CSF to increase the number of stem cells that can be collected prior to bone marrow transplantation. Mozobil may offer a specific and well-tolerated new treatment for WHIMS and other syndromes characterized by neutropenia.\n\nObjectives:\n\n* To evaluate whether Mozobil is safe and effective to treat neutropenia (low white blood cell count) in patients with WHIMS.\n* To determine an appropriate treatment dose of Mozobil, within currently approved dosage levels.\n\nEligibility:\n\n\\- Individuals between 18 and 75 years of age who have been diagnosed with WHIMS and have a history of severe infections.\n\nDesign:\n\n* Potential participants will undergo a screening with a medical history, physical examination, questionnaire, heart and lung function scans, and blood and urine samples. Tests will also be done for hepatitis B and C virus, and human immunodeficiency virus (HIV) that causes acquired immunodeficiency syndrome (AIDS), as well as to check neutrophil function.\n* Patients who are being treated with G-CSF will stop injections for 2 days before being admitted to the National Institutes of Health (NIH) Clinical Center.\n* Patients may participate in a Dose Escalation study and receive increasing doses of Mozobil over 5 days of treatment until their white blood cell count improves sufficiently or the maximum approved dose is reached. Blood samples will be taken regularly throughout the treatment process. Patients will then receive an additional dose of Mozobil at the maximum approved dose or the dose sufficient to cause improvement, before restarting the G-CSF injections.\n* Patients may also participate in a long-term Chronic Dosing study and receive Mozobil once or twice a day for up to a maximum of 60 months.",[28,29,30,31,32],"Leukopenia","Neutropenia","Infections","Warts","Myelokathexis",[29,34,32,31,35],"Hypogammaglobulinemia","Immunodeficiency","RECRUITING","2026-06-27",{"date":39,"type":40},"2026-06-30","ACTUAL",{"date":42,"type":40},"2010-01-06",{"date":44,"type":21},"2026-12-31",{"name":46,"class":47},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":4,"leadSponsor":75,"locationsCount":48},"100122933","etiology-pathogenesis-and-natural-history-of-idiopathic-cd4-lymphocytopenia-100122933","NCT00867269","Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia","* ICL PARTICPANT INCLUSION CRITERIA:\n\nTo be eligible for this study, patients must satisfy all of the following inclusion criteria:\n\n1. Age greater than or equal to 18 years\n2. Absolute CD4 count \\\u003C 300 cells\u002FmicroL or \\\u003C 20% of total T cells on at least two occasions at least 6 weeks apart\n3. Ongoing care by a referring primary care physician\n4. Willingness to allow storage of blood and tissue samples for future analysis\n\nICL PARTICPANT EXCLUSION CRITERIA:\n\nPatients will be ineligible for this study if they satisfy any of the following criteria:\n\n1. Known infection with HIV-1, HIV-2, or human T-cell lymphotropic viruses (HTLV-1 or HTLV-2) as demonstrated by enzyme-linked immunosorbent assay (ELISA) and western blot and\u002For viral load testing\n2. Known underlying immunodeficiency syndrome other than ICL\n3. Evidence of active malignancy\n4. Receipt of medications, herbal substances, or biologic agents known to diminish the CD4+ count within 30 days of when the CD4+ lymphocytopenia was detected\n5. Any condition that in the judgment of the investigators would place the subject at undue risk or compromise the results of the study.\n\nBLOOD RELATIVE INCLUSION CRITERIA:\n\nTo be eligible for study participation as a blood relative, subjects must be greater than or equal to 18 years of age and be a blood relative of an individual who meets or has met the CDC criteria for ICL.\n\nHOUSEHOLD CONTACT INCLUSION CRITERIA:\n\nTo be eligible for study participation as a household contact, subjects must be greater than or equal to18 years of age and live within the same household as an ICL subjects participating in this protocol. Blood relatives who are household contacts are eligible to participate.",true,{"count":57,"type":21},950,"OBSERVATIONAL","Background:\n\n* Idiopathic CD4+ lymphocytopenia (ICL) is a condition in which there is a decreased level of CD4+ lymphocytes (a type of white blood cell), which can lead to opportunistic infections or autoimmune disorders and diseases.\n\nObjectives:\n\n* To characterize the natural history with regard to CD4+ T cell count and onset of infection, malignancy, and autoimmunity.\n* To describe the immunological status of patients affected by ICL while providing the best possible standard therapy to eradicate opportunistic infections.\n* To establish the timeline of CD4 lymphocytopenia, with particular focus on defining subgroups of patients according to the decline, stabilization, or rise of CD4+ T cell counts over time.\n* To characterize the opportunistic infections that occur in ICL patients at microbiologic and molecular levels.\n* To characterize the immunophenotype and possible genetic immunodeficiency causes of ICL.\n* To determine whether measurable immunologic parameters correlate with the development of opportunistic infections or other comorbidities such as lymphoma in patients with ICL.\n* To determine whether there is any association between ICL and autoimmunity.\n* To determine CD4+ T cell turnover, survival, functionality, and cytokine responsiveness in ICL patients.\n\nEligibility:\n\n* Patients 2 years of age and older with an absolute CD4 count less than 300 in children 6 years or older and adults or less than 20% of T cells in children younger than 6 on two occasions at least 6 weeks apart.\n* Patients with negative results of HIV testing by ELISA, Western Blot, and viral load.\n* Patients must not have underlying immunodeficiency conditions, be receiving cytotoxic chemotherapy (anti-cancer drugs that kill cells), or have cancer.\n\nDesign:\n\n* At the initial visit to the National Institutes of Health, the following evaluations will be conducted:\n* Personal and family medical histories.\n* Physical examination, including rheumatology evaluation and other consultations as medically indicated (e.g., dermatology, pulmonology, ophthalmology, imaging studies).\n* Blood samples for analysis of red and white blood cell counts, liver function, immune hormones, and antibody and autoantibody levels, white blood cell growth and function, and DNA.\n* Urinalysis and urine pregnancy testing for female patients of childbearing age.\n* Evaluation and treatment of active infections as medically indicated, including biopsies, buccal swabs, pulmonary function tests, and imaging studies.\n* Follow-up visits will take place approximately every 12 months or more frequently if indicated, and will continue for a minimum of 4 years and a maximum of 10 years.\n* Evaluations at follow-up will include blood samples (i.e., CBC with differential, biochemical profile, HIV testing, etc.) and urinalysis and rheumatology consults.",[61,62,31],"Idiopathic CD4+ Lymphocytopenia","Cryptococcal Meningitis",[64,65,66,67,68,69],"Opportunistic Infection","Immunodeficiency Syndrome","Autoimmune Disease","CD4+ Lymphocytes","Natural History","Idiopathic CD4 Lymphocytopenia","2026-06-17",{"date":72,"type":40},"2026-06-18",{"date":74,"type":40},"2009-07-13",{"name":46,"class":47},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":106},"100643507","phase-3-cantharidin-application-in-patients-with-common-warts-verruca-vulgaris-cove-3-100643507","NCT07637734","Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)","COVE-3: A Phase 3, Double-blind, Randomized, Vehicle-controlled Study to Evaluate the Efficacy and Safety of YCANTH (VP-102\u002FTO-208) in Subjects With Common Warts (Verruca Vulgaris)","COVE-3","Inclusion Criteria:\n\nCandidates will be included in the study if they:\n\n1. Are male or female patients ≥ 2 years of age.\n2. Are immunocompetent.\n3. Have a minimum of 1 treatable common wart (verruca vulgaris) of any size and height:\n\n   1. Common warts are considered treatable if they are located anywhere on the body, except for the following excluded areas: the eye area (including eyelids), lips, oral cavity, nasal cavity, inside of the ears, soles of the feet (plantar warts), subungual spaces (ie, under the fingernail or toenail), or the anogenital area (warts within 10 mm of a mucosal surface should not be treated).\n   2. Common warts located in excluded areas (warts within 10 mm of a mucosal surface) will not be treated or evaluated in this study. Warts that are genital, plantar, or anal are not considered common warts and are thus excluded from treatment and evaluation in this study. A subject will not be excluded from the study if they have these types of warts, but the subject must also have warts that meet the inclusion criteria. • If treatment of these excluded wart types is required during the study, it should be limited to destructive therapy such as cryosurgery and warts cannot be within 10 mm of any warts that are under study.\n4. Have no systemic or dermatologic disorder, which, in the opinion of the Investigator, will interfere with the study results or increase the risk of AEs.\n5. Agree to refrain from swimming, bathing, or prolonged immersion in water or any liquids until the study drug is removed after each treatment.\n6. Have the ability, or have a parent\u002Fguardian with the ability, to follow study instructions and the willingness to complete all study requirements.\n7. Agree not to use any wart-removing product (prescription or over-the-counter) other than the study drug during the course of the study, with the exception of circumstances allowed under Inclusion Criterion 3b.\n8. Provide written informed consent or assent in a manner approved by the IRB and\u002For have a parent\u002Fguardian provide written informed consent as evidenced by the signature on an IRB approved assent\u002Fconsent form. Subjects who turn 18 years of age (or legal age per state or country) during the study will be required to re-consent to remain on the study.\n9. Provide written authorization for use and disclosure of protected health information (per state and\u002For country requirements).\n10. If participating in the optional photographic assessment, agree to allow photographs of treatable common warts to be taken at selected visits by the research team.\n\nExclusion Criteria:\n\nCandidates will be excluded from the study if they:\n\n1. Are unable to cooperate with the requirements or visits of the study, as determined by the Investigator.\n2. Have any warts present at Baseline in an allowed anatomic location that the subject, parent\u002Fguardian, or Investigator is unwilling to treat.\n3. Plantar warts and external genital warts will not be included in this study, in addition, subungual warts and warts within 10 mm of a mucosal surface will not be included in this study due to their anatomical location and complex treatment modalities.\n4. Are systemically immunosuppressed or have taken required systemic immunosuppressive or immunomodulatory medication (including oral or parenteral corticosteroids) within 30 days before enrollment or such treatment is planned to be required during the course of the study. Routine use of local (eg, topical, inhaled, intranasal) corticosteroids and episodic use of systemic medications to treat conditions arising during the study is allowed.\n5. Have any chronic or acute medical condition that, in the opinion of the Investigator, may interfere with the study results or place the subject at undue risk (eg, human immunodeficiency virus, systemic lupus erythematosus, viral hepatitis, uncontrolled diabetes).\n6. Have had any previous treatment (including an investigational agent in a clinical trial) of common warts, including but not limited to the use of cantharidin, imiquimod, antivirals, retinoids, topical salicylic acid, lactic acid, hydrogen peroxide, trichloroacetic acid, pulse dye laser, iodine-based or nitric oxide-based therapies, oral cimetidine, coix seed, intralesional immunotherapy, curettage, or freezing of warts in the 30 days before treatment.\n7. Have more common warts, or wart area, to be treated than can be adequately covered with the contents of 2 study drug applicators, as determined by total wart surface area. Each applicator can cover approximately 1500 mm2 for a total of approximately 3000 mm2 using the 2 study drug applicators.\n8. Immunizations (eg, flu shots) may be administered throughout the study, but not within 5 days before or after any treatment with study drug and will be recorded as concomitant therapies in the eCRF.\n9. Have received any investigational product as part of a clinical trial NOT related to the treatment of common warts within 30 days before the first application of the study drug.\n10. Have epidermodysplasia verruciformis.\n11. Have an active malignancy or are undergoing treatment for any malignancy.\n12. Have a history or presence of clinically significant medical, psychiatric, or emotional condition or abnormality that, in the opinion of the Investigator, would compromise the safety of the subject or the quality of the data.\n13. Have a history or presence of hypersensitivity or an idiosyncratic reaction to the study drug or related compounds, or drug product excipients (acetone, ethyl alcohol, nitrocellulose, hydroxypropyl cellulose, castor oil, camphor, gentian violet, and denatonium benzoate).\n14. Have a condition or situation that may interfere significantly with the subject's participation in the study (eg, subjects who required hospitalization in the 2 months before screening for an acute or chronic condition including alcohol or drug abuse), as determined by the Investigator.\n15. Are sexually active or may become sexually active and are unwilling to practice a highly effective method of birth control (eg, combination of condoms and foam; oral contraceptives; intrauterine device with or without hormone release; transdermal, injectable, or intravaginal contraception). Withdrawal is not an acceptable method of birth control. Females who have reached menarche must have a negative urine pregnancy test at each visit before treatment with study drug.\n16. Are pregnant or breastfeeding.","2 Years",{"count":86,"type":21},300,[88],"PHASE3","This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-302; referred to as COVE-3 \\[Cantharidin and Occlusion in Verruca Epithelium\\]) to evaluate the efficacy and safety of YCANTH (VP-102\u002FTO-208) treatment in subjects with common warts.",[91,92,93,31],"Common Warts","Common Warts (Verruca Vulgaris)","Human Papilloma Virus (HPV)",[91,92,93],"NOT_YET_RECRUITING","2026-06-09",{"date":98,"type":40},"2026-06-10",{"date":100,"type":21},"2026-06",{"date":102,"type":21},"2027-10",{"name":104,"class":105},"Verrica Pharmaceuticals Inc.","INDUSTRY",2,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":120,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},"100628152","phase-3-long-term-follow-up-study-of-cantharidin-ycanth-vp-102to-208-in-patients-with-common-warts-verruca-vulgaris-100628152","NCT07457918","Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102\u002FTO-208]) in Patients With Common Warts (Verruca Vulgaris)","COVE-4: A Phase 3, Open-Label, Long-Term Follow-Up Study to Evaluate the Safety and Efficacy of YCANTH (VP-102\u002FTO-208) in Subjects With Common Warts (Verruca Vulgaris)","COVE-4","Inclusion Criteria:\n\nCandidates will be included in the study if they:\n\n1. Meet ≥ 1 of the following criteria:\n\n   1. Completed the Day 84 visit in the parent study and have ≥ 1 treatable common warts.\n   2. Completed the Day 105 visit in the parent study and have ≥ 1 treatable common warts.\n   3. Completed the Day 147 visit in the parent study.\n2. Provide written informed consent or assent in a manner approved by the Institutional Review Board (IRB) and\u002For have a parent\u002Fguardian provide written informed consent as evidenced by the signature on an IRB approved assent\u002Fconsent form. Subjects who turn 18 years of age (or legal age per state or country) during the study may be required to re consent to remain on the study (follow the state or country regulatory requirements).\n3. Agree to refrain from swimming, bathing, or prolonged immersion in water or any liquids until the study drug is removed after each treatment.\n4. Have the ability, or have a parent\u002Fguardian with the ability, to follow study instructions and the willingness to complete all study requirements.\n5. Agree not to use any wart-removing product (prescription or over-the-counter) other than the study drug during the course of the study with the exception of circumstances for excluded wart types. Excluded warts include common warts located in excluded areas that will not be treated or evaluated during the study as well as genital, plantar, or anal warts:\n\n   a. If treatment of these excluded wart types is required during the study, it should be limited to destructive therapy such as cryosurgery and warts cannot be within 10mm of any warts that are under study.\n6. Provide written authorization for use and disclosure of protected health information (per state and\u002For country requirements).\n7. If participating in the optional photographic assessment, agree to allow photographs of treatable common warts to be taken at selected visits by the research team.\n\nExclusion Criteria:\n\nCandidates will be excluded from the study if they:\n\n1. Are unable to cooperate with the requirements or visits of the study, as determined by the Investigator.\n2. Have any warts present at study entry in an allowed anatomic location that the subject, parent\u002Fguardian, or Investigator is unwilling to treat.\n3. Are systemically immunosuppressed or have taken required systemic immunosuppressive or immunomodulatory medication (including oral or parenteral corticosteroids) within 30 days before enrollment or such treatment is planned to be required during the course of the study. Routine use of local (eg, topical, inhaled, intranasal) corticosteroids and episodic use of systemic medications to treat conditions arising during the study is allowed.\n4. Have any chronic or acute medical condition that, in the opinion of the Investigator, may interfere with the study results or place the subject at undue risk (eg, human immunodeficiency virus, systemic lupus erythematosus, viral hepatitis, uncontrolled diabetes).\n5. Have had any previous treatment (including an investigational agent in a clinical trial) of common warts, including but not limited to the use of cantharidin, imiquimod, antivirals, retinoids, topical salicylic acid, lactic acid, hydrogen peroxide, trichloroacetic acid, pulse dye laser, iodine-based or nitric oxide-based therapies, oral cimetidine, coix seed, intralesional immunotherapy, curettage, or freezing of warts in the 30 days before treatment.\n6. Immunizations (eg, flu shots) may be administered throughout the study, but not within 5 days before or after any treatment with study drug.\n7. Have received any investigational product as part of a clinical trial NOT related to the treatment of common warts within 30 days before the first application of the study drug.\n8. Have epidermodysplasia verruciformis.\n9. Have an active malignancy or are undergoing treatment for any malignancy.\n10. Have a clinically significant medical, psychiatric, emotional condition, or abnormality that, in the opinion of the Investigator, would compromise the safety of the subject or the quality of the data.\n11. Have a hypersensitivity or an idiosyncratic reaction to YCANTH (VP-102\u002FTO-208) or related compounds, or drug product excipients (acetone, ethyl alcohol, nitrocellulose, hydroxypropyl cellulose, castor oil, camphor, gentian violet, and denatonium benzoate).\n12. Have a condition or situation that may interfere significantly with the subject's participation in the study (eg, subjects who require hospitalization for an acute or chronic condition including alcohol or drug abuse), at the determination of the Investigator.\n13. Are sexually active or may become sexually active and are unwilling to practice responsible birth control methods (eg., combination of condoms and foam, birth control pills, intrauterine device, patch, shot and vaginal ring). Withdrawal is not an acceptable method of birth control. Females who have reached menarche must have a negative urine pregnancy test at each visit before treatment with YCANTH (VP-102\u002FTO-208).\n14. Are pregnant or breastfeeding.",{"count":116,"type":21},600,[88],"People who participated in either the COVE-2 or COVE-3 study for common warts, may be eligible to enroll into this Long Term Follow Up (LTFU) study COVE-4. The main question(s) to answer in this LTFU study are:\n\n* To assess the safety of YCANTH (also known as VP-102 in the United Sates or TO-208 in Japan) by assessing concomitant medication use, and adverse events (AEs), including expected local skin reactions (LSRs).\n* To evaluate the efficacy of continued skin application of YCANTH (VP-102\u002FTO-208) when applied to each common wart once every 21 days for a maximum of 4 additional treatments.\n\nParticipants with eligible common warts present will receive YCANTH (VP-102\u002FTO-208) with an interval of 21 (± 4) days between applications until there is a wart count of zero (ie, completed clearance has been achieved) or a maximum of 4 additional treatments. Participants with complete clearance will attend Observation Visits at intervals of 42 (± 4) days without treatment. Participants who develop a new wart after having a wart count of zero will resume Treatment Visits every 21 (± 4) days for a maximum of 4 additional treatments. All subjects will attend visits until the End-of-Study (EOS) Visit, which is on Day 378 (0\u002F+ 8 days).\n\nIf participants still have warts present after 4 additional treatments of YCANTH (VP-102\u002FTO-208) the wart(s) will be discontinued from study and participants will be allowed to seek treatment but should be limited to destructive therapy such as cryosurgery and warts cannot be within 10 mm of any warts that receive(d) study drug treatment . The exact interval of Treatment Visits will be determined by evaluation of the treatment site, taking into account any ongoing local skin reactions (LSRs), which are defined as temporary application site:\n\nvesiculation, pain, pruritus, scabbing, erythema, discoloration, dryness, edema and erosion that is expected and consistent with historical treatment with YCANTH (VP-102\u002FTO-208). Participants may receive treatment until all treatable common warts are clear, up to a maximum of 4 treatment sessions, or until Day 357, whichever occurs first.\n\nTreatment:\n\nFor participants with warts present at the time of study entry, the first treatment application may occur on the same day as transition from the parent study. All required parent study assessments must be complete, including the final evaluation of response to treatment (ERT; as defined in Assessments and procedures).\n\nIn addition, eligibility for participation in the LTFU study must have been determined, and informed consent\u002Fassent for participation in this LTFU study obtained. YCANTH (VP-102\u002FTO-208) will be applied by the Investigator or qualified member of the research team to treatable common warts, including an approximate 1 to 2 mm margin of healthy, surrounding skin. After YCANTH (VP-102\u002FTO- 208) is applied, warts are to be covered with occlusive tape (occlusive tape with similar properties should be used across all clinical sites) that will remain in place overnight and should be removed 24 hours after application of study drug and just before a 24-hour ERT. Before application of study drug, wart paring, if necessary, will be completed with a sharp surgical instrument (eg, scalpel or flexible medical blade) to remove any adherent thick scale from a treatable common wart. Wart paring is required to be performed at any treatment visit when adherent thick scale is present, and the Investigator feels paring can be safely performed. Paring should be conducted by a trained practitioner and in compliance with any local regulations and should be discontinued if it results in punctate bleeding or significant pain. Not all treatable common warts may require paring. If adherent scale is not present, study drug can be applied without paring. The assessment for complete clearance may be made once all treatable common warts are evaluable and not obscured by an ongoing LSR. If the Investigator is unable to evaluate or treat 1 or more warts due to ongoing LSRs, no warts should be treated, and the visit will be documented as an Unscheduled Visit. The timing of the next treatment visit will be determined by resolution of the LSRs. The research team will be in contact with the Participant until all LSRs are resolved. Once LSRs have resolved, a Treatment Visit will be scheduled within 21 (± 4) days of the previous treatment application, noting it may be longer than 21 (± 4) days depending on the length of time until LSR resolution. All treatable common warts that are not completely clear should undergo treatment with study drug. Study duration from Days 84, 105, or 147 of the parent study (COVE-2 or COVE-3) through the final EOS visit of this LTFU study (Day 378) is approximately 294 days.",[92,91,93,31],[92,91,93],"2026-04-30",{"date":123,"type":40},"2026-05-05",{"date":125,"type":40},"2026-03-11",{"date":127,"type":21},"2028-05-22",{"name":104,"class":105},4,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":137,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":48},"100634067","hyperthermia-combined-with-hydrogen-peroxide-microneedle-patch-for-viral-warts-100634067","NCT07534865","Hyperthermia Combined With Hydrogen Peroxide Microneedle Patch for Viral Warts","A Randomized, Parallel-Group, Controlled, Assessor-Blinded Clinical Trial of Hyperthermia Combined With Hydrogen Peroxide Microneedle Patch for Viral Warts","Inclusion Criteria:\n\n1. Age 6-65 years, male or female;\n2. Clinically diagnosed with common warts, palmar\u002Fplantar\u002Fdigital warts (≥1 lesion), with a Physician's Wart Assessment score ≥2 (0: no visible wart, no further treatment required; 1: visible wart, diameter \\\u003C3 mm; 2: single wart diameter ≥3 mm and \\\u003C6 mm; 3: single wart diameter ≥6 mm);\n3. The subject or legal guardian is able to understand and sign the informed consent form and agrees to participate in the study.\n\nExclusion Criteria:\n\n1. Subjects presenting with atypical warts clinically;\n2. Subjects with immune dysfunction or autoimmune diseases;\n3. Pregnant or breastfeeding women;\n4. Subjects who have received human papillomavirus (HPV) vaccination within the past 6 months;\n5. Subjects who have undergone the following systemic treatments within the specified time frames: immunomodulators\u002Fimmunosuppressants (e.g., etanercept), within 4 months; corticosteroids (inhaled and intranasal use permitted), within 1 month;\n6. Subjects who have received the following treatments on or around the warts within the specified time frames: laser or other photochemical therapies (intense pulsed light, photodynamic therapy), within 3 months; immunotherapy (candida antigen), within 4 months; cryotherapy with liquid nitrogen, within 2 months; hydrogen peroxide, within 3 months; antimetabolite therapy (5-fluorouracil), within 2 months; retinoids, within 3 months;\n7. Subjects with a history of the following diseases prior to enrollment: skin malignancy within the past 6 months, premalignant skin conditions (actinic keratosis) within the past 6 months, or currently in the acute progressive phase of skin or systemic diseases (e.g., psoriasis, atopic dermatitis, eczema, sun damage, etc.) or presenting with conditions (such as sunburn, open wounds) that may increase the risk of participation or interfere with evaluation;\n8. Subjects with diseases affecting skin healing, such as diabetes mellitus, vitamin A deficiency, etc.;\n9. Subjects with cold-sensitive conditions such as cryoglobulinemia or cold urticaria that may lead to abnormal observation results;\n10. Subjects with severe dysfunction of the heart, lung, liver, kidney, hematopoietic system, or other vital organs.","6 Years","65 Years",{"count":140,"type":21},210,[142],"NA","Hyperthermia treatment (hyperthermia) refers to treating diseases with temperature (39-45 ° C) beyond normal body temperature,. It has been reported that local warming at 44 ° C is able to effectively mobilize the body's immunity and clear HPV infected lesions, such as condyloma acuminatum and verruca vulgaris, etc. Significant progress has been made in the application of hyperthermia for viral skin diseases. Clinically, the addition of hydrogen peroxide solution can enhance the efficacy of hyperthermia in treating HPV infection. As a common transdermal drug delivery method, microneedles can increase drug penetration and thereby further improve treatment outcomes. Based on these findings, this study aims to explore an adjunctive approach to hyperthermia for treating viral warts to further enhance therapeutic efficacy.\n\nThis study employs a randomized, parallel-group, assessor-blinded design. Participants will be randomly assigned to three groups: hyperthermia alone, hyperthermia combined with microneedle patch (loaded with 0.9% saline), and hyperthermia combined with hydrogen peroxide microneedle patch (experimental group). An adaptive design will be adopted. The sample size is estimated at 70 participants per group, accounting for a potential 20% dropout rate. Interim analyses will be conducted during follow-up, and enrollment will be stopped when a positive result is reached for the primary efficacy endpoint (cure rate), at which point the sample size will be adjusted accordingly.",[31],"2026-04-10",{"date":147,"type":40},"2026-04-16",{"date":149,"type":21},"2026-05-01",{"date":151,"type":21},"2028-12-01",{"name":153,"class":154},"First Hospital of China Medical University","OTHER",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":162,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":166,"briefSummary":168,"conditions":169,"keywords":170,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":4},"100623444","early-phase-1-the-efficacy-of-ivermectin-alone-or-with-microneedling-in-treatment-of-cutaneous-warts-100623444","NCT07396714","the Efficacy of Ivermectin Alone or With Microneedling in Treatment of Cutaneous Warts.","Evaluation of the Efficacy & Safety of Topical Ivermectin Alone or in Combination With Microneedling as Novel Therapeutic Options for Cutaneous Non-genital Warts Versus Topical Salicylic Acid ؛ Randomized Controlled Clinical Trial.","Inclusion Criteria:\n\n* patients with cutaneous non genital warts aged 11:80 y.\n* No concurrent systemic or topical treatment of warts\n\nExclusion Criteria:\n\n* Genital warts.\n\n  * Pregnancy and lactation.\n  * History of any bleeding, clotting disorder or using anticoagulants\n  * Chronic systemic diseases such as chronic renal failure, hepaticinsufficiency, and cardiovascular disorders.\n  * patients who received any treatment for warts in the last month before the study.\n  * Patients with history of neuropathy or peripheral ischemia.\n  * Patients with signs of inflammation or infection.\n  * Patients with history of a serious systemic or anaphylactic reaction or allergy to ivermectin.","11 Years","80 Years",{"count":165,"type":21},88,[167],"EARLY_PHASE1","To compare between the efficacy and safety of topical ivermectin alone, microneedling with topical ivermectin and topical salicylic acid in treatment of cutaneous warts.\n\ntopical ivermectin 1% will be applied on warts whole night clinical assessment will be done every 2 weeks\n\nMicroneedling will be performed on the lesion using a microneedling pen type device with a 1-cm tip diameter at a 2-mm depth setting for 2-3 minutes until pinpoint bleebing occurs 1 mL of topical ivermectin 1% will be applied on to the wart tissue.\n\nSessions: Sessions will be performed every 2 weeks until complete cure or for maximum 6 sessions (total 3 month)",[31],[171],"topical ivermectin with microneedling in warts treatment","2026-02-04",{"date":174,"type":40},"2026-02-09",{"date":176,"type":21},"2026-02-01",{"date":178,"type":21},"2027-06-01",{"name":180,"class":154},"Assiut University",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":22,"phases":190,"briefSummary":191,"conditions":192,"keywords":193,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":202},"100611900","phase-3-cantharidin-application-in-patients-with-common-warts-verruca-vulgaris-cove-2-100611900","NCT07246590","Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)","COVE-2: A Phase 3, Double-blind, Randomized, Vehicle-controlled Study to Evaluate the Efficacy and Safety of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris)","COVE-2","Inclusion Criteria:\n\nCandidates will be included in the study if they:\n\n1. Are male or female patients ≥ 2 years of age.\n2. Are immunocompetent.\n3. Have a minimum of 1 treatable common wart (verruca vulgaris) of any size and height:\n\n   1. Common warts are considered treatable if they are located anywhere on the body, except for the following excluded areas: the eye area (including eyelids), lips, oral cavity, nasal cavity, inside of the ears, soles of the feet (plantar warts), subungual spaces (ie, under the fingernail or toenail), or the anogenital area (warts within 10 mm of a mucosal surface should not be treated).\n   2. Common warts located in excluded areas (warts within 10 mm of a mucosal surface) will not be treated or evaluated in this study. Warts that are genital, plantar, or anal are not considered common warts and are thus excluded from treatment and evaluation in this study. A subject will not be excluded from the study if they have these types of warts, but the subject must also have warts that meet the inclusion criteria.\n\n      * If treatment of these excluded wart types is required during the study, it should be limited to destructive therapy such as cryosurgery and warts cannot be within 10 mm of any warts that are under study.\n4. Have no systemic or dermatologic disorder, which, in the opinion of the Investigator, will interfere with the study results or increase the risk of AEs.\n5. Agree to refrain from swimming, bathing, or prolonged immersion in water or any liquids until the study drug is removed after each treatment.\n6. Have the ability, or have a parent\u002Fguardian with the ability, to follow study instructions and the willingness to complete all study requirements.\n7. Agree not to use any wart-removing product (prescription or over-the-counter) other than the study drug during the course of the study, with the exception of circumstances allowed under Inclusion Criterion 3b.\n8. Provide written informed consent or assent in a manner approved by the IRB and\u002For have a parent\u002Fguardian provide written informed consent as evidenced by the signature on an IRB approved assent\u002Fconsent form. Subjects who turn 18 years of age (or legal age per state or country) during the study will be required to re-consent to remain on the study.\n9. Provide written authorization for use and disclosure of protected health information (per state and\u002For country requirements).\n10. If participating in the optional photographic assessment, agree to allow photographs of treatable common warts to be taken at selected visits by the research team.\n\nExclusion Criteria:\n\nCandidates will be excluded from the study if they:\n\n1. Are unable to cooperate with the requirements or visits of the study, as determined by the Investigator.\n2. Have any warts present at Baseline in an allowed anatomic location that the subject, parent\u002Fguardian, or Investigator is unwilling to treat.\n3. Plantar warts and external genital warts will not be included in this study, in addition, subungual warts and warts within 10 mm of a mucosal surface will not be included in this study due to their anatomical location and complex treatment modalities.\n4. Are systemically immunosuppressed or have taken required systemic immunosuppressive or immunomodulatory medication (including oral or parenteral corticosteroids) within 30 days before enrollment or such treatment is planned to be required during the course of the study. Routine use of local (eg, topical, inhaled, intranasal) corticosteroids and episodic use of systemic medications to treat conditions arising during the study is allowed.\n5. Have any chronic or acute medical condition that, in the opinion of the Investigator, may interfere with the study results or place the subject at undue risk (eg, human immunodeficiency virus, systemic lupus erythematosus, viral hepatitis, uncontrolled diabetes).\n6. Have had any previous treatment (including an investigational agent in a clinical trial) of common warts, including but not limited to the use of cantharidin, imiquimod, antivirals, retinoids, topical salicylic acid, lactic acid, hydrogen peroxide, trichloroacetic acid, pulse dye laser, iodine-based or nitric oxide-based therapies, oral cimetidine, coix seed, intralesional immunotherapy, curettage, or freezing of warts in the 90 days before treatment.\n7. Have more common warts, or wart area, to be treated than can be adequately covered with the contents of 2 study drug applicators, as determined by total wart surface area. Each applicator can cover approximately 1500 mm2 for a total of approximately 3000 mm2 using the 2 study drug applicators.\n8. Immunizations (eg, flu shots) may be administered throughout the study, but not within 5 days before or after any treatment with study drug and will be recorded as concomitant therapies in the eCRF.\n9. Have received any investigational product as part of a clinical trial NOT related to the treatment of common warts within 30 days before the first application of the study drug.\n10. Have epidermodysplasia verruciformis.\n11. Have an active malignancy or are undergoing treatment for any malignancy.\n12. Have a history or presence of clinically significant medical, psychiatric, or emotional condition or abnormality that, in the opinion of the Investigator, would compromise the safety of the subject or the quality of the data.\n13. Have a history or presence of hypersensitivity or an idiosyncratic reaction to the study drug or related compounds, or drug product excipients (acetone, ethyl alcohol, nitrocellulose, hydroxypropyl cellulose, castor oil, camphor, gentian violet, and denatonium benzoate).\n14. Have a condition or situation that may interfere significantly with the subject's participation in the study (eg, subjects who required hospitalization in the 2 months before screening for an acute or chronic condition including alcohol or drug abuse), as determined by the Investigator.\n15. Are sexually active or may become sexually active and are unwilling to practice a highly effective method of birth control (eg, combination of condoms and foam; oral contraceptives; intrauterine device with or without hormone release; transdermal, injectable, or intravaginal contraception). Withdrawal is not an acceptable method of birth control. Females who have reached menarche must have a negative urine pregnancy test at each visit before treatment with study drug.\n16. Are pregnant or breastfeeding.",{"count":86,"type":21},[88],"This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 \\[Cantharidin and Occlusion in Verruca Epithelium\\]) to evaluate the efficacy and safety of YCANTH (VP-102) treatment in subjects with common warts.",[91,92,93,31],[91,92,93],"2026-01-19",{"date":196,"type":40},"2026-01-21",{"date":198,"type":40},"2025-12-17",{"date":200,"type":21},"2027-06",{"name":104,"class":105},6,{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":22,"phases":212,"briefSummary":213,"conditions":214,"keywords":215,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":48},"100579718","multicenter-real-world-study-of-hyperthermia-in-warts-of-special-population-100579718","NCT06827938","Multicenter Real-World Study of Hyperthermia in Warts of Special Population","Multicenter Real-World Study of Hyperthermia in Skin\u002FMucosal HPV Infection of Special Population","Inclusion Criteria:\n\n1. Pregnant women with viral warts\n2. Diagnosis of AIDS with viral warts\n3. Autoimmune disease patients with viral warts\n4. Diabetic patients with viral warts\n5. Patients with viral warts who are currently being treated with immunosuppressants\n6. Children with viral warts\n7. The subject or legal guardian is able to understand and sign the informed consent\u002Fconsent to participate in the study\n\nExclusion Criteria:\n\n1. The subject suffers from tumor or other serious disease and cannot complete this clinical study\n2. Timely treatment and follow-up cannot be guaranteed due to personal or other objective reasons",{"count":211,"type":21},400,[142],"Hyperthermia refers to treating diseases with temperatures beyond normal body temperature (39-45℃), and moxibustion therapy of traditional Chinese medicine belongs to the category of hyperthermia. It has been reported at home and abroad that the local temperature of 44℃ can effectively mobilize the body's immunity and remove HPV infection lesions, such as condyloma acuminatum and verruca vulgaris. Our research group conducted randomized controlled experiments on patients with viral warts in the early clinical practice, and the cure rate of the hyperthermia group reached 45-55%, which was superior to the traditional method in the aspects of no trauma, low recurrence rate, easy to tolerate and so on. Our research group's preliminary research on hyperthermia of viral warts has been included in the British Medical Association's guidelines for viral warts therapy. The equipment our research group developed has been obtained the medical device registration certificate, and is in the process of national promotion. Hyperthermia is to mobilize systemic immunity through local warm heat, the preliminary clinical study of the research group shows that the therapeutic effect of hyperthermia is usually \"all or none\": \"all\" that is, after hyperthermia, all viral warts are removed, including non-treatment lesions;\"None\" means that some patients with viral warts do not respond to hyperthermia. Cellular immunity plays a very important role in the removal of warts. At present, some special clinical patients such as pregnant women, children, patients with autoimmune diseases, diabetes, immunosuppressants after organ transplantation and other patients with skin\u002Fmucosal HPV infection, their warts show more extensive proliferation or a longer and repeated course of disease, treatment resistance, etc. It has increased the difficulty of clinical treatment, and the specific mechanism is still unclear. Therefore, for these special populations, how to further enhance the therapeutic effect of hyperthermia is the top priority of current research.\n\nIn view of the above findings, this research group intends to study the efficacy and safety of hyperthermia in the treatment of viral warts in the special population (pregnant women, children, patients with autoimmune diseases, diabetes, and immunosuppressants after organ transplantation, etc.) in a multicenter real-world study of skin\u002Fmucosal HPV infection in the special population.",[31],[216,217],"warts","local hyperthermia","2025-08-09",{"date":220,"type":40},"2025-08-14",{"date":222,"type":40},"2024-07-10",{"date":224,"type":21},"2027-07-10",{"name":153,"class":154},{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":16,"minAge":233,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":48},"100461683","phase-2-candida-antigen-and-bivalent-hpv-vaccine-in-the-treatment-of-multiple-warts-100461683","NCT05291845","Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts","Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts: Monotherapy Versus Combined Therapy","Inclusion Criteria:\n\n* patients with multiple, recalcitrant, or non-recalcitrant common warts of different sites, sizes, duration, and with or without distant lesions will be enrolled in the study\n\nExclusion Criteria:\n\n* Pregnant female. Hypersensitivity to Candida antigen or bivalent HPV vaccine","9 Years",{"count":235,"type":21},162,[25],"To follow up the efficacy and safety of Candida antigen, bivalent HPV vaccine in treatment of common warts either mono or combined intralesional therapy",[31,239],"Human Papilloma Virus","2025-06-09",{"date":242,"type":40},"2025-06-12",{"date":244,"type":40},"2022-04-03",{"date":246,"type":21},"2025-12-06",{"name":248,"class":249},"Zagazig University","OTHER_GOV",{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":55,"sex":16,"minAge":17,"maxAge":257,"enrollmentInfo":258,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":260,"conditions":261,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":4},"100590903","combination-therapy-of-imiquimod-5cream-and-cryotherapy-vs-monotherapy-for-common-wartsrandomized-comparative-trial-100590903","NCT06973473","Combination Therapy of Imiquimod 5%Cream and Cryotherapy vs Monotherapy for Common Warts:Randomized Comparative Trial.","Aprospective,Randomized,Comparative Clinical Trial of Combination Therapy of Imiquimod 5%Cream and Cryotherapy vs Monotherapy for Common Warts.","Inclusion Criteria:\n\n* Patients with common warts diagnosed clinically and by dermoscopy.\n* Patients older than 18years old.\n\nExclusion Criteria:\n\n* Pregnancy and lactation.\n* Immunosuppression or being under any kind of treatment causing\n* absolute or relative immunosuppression.\n* Patients with chronic systemic diseases.\n* All cases of bleeding tendency or using anticoagulants.\n* Concurrent use of systemic or topical treatments of warts in the last 4 weeks.","60 Years",{"count":259,"type":21},60,"To assess the clinical efficacy and safety of topical imiquimod 5% cream combined with cryotherapy versus either of theme alone for the treatment of common warts by clinical and dermoscopic assessments.",[31],"2025-05-07",{"date":264,"type":40},"2025-05-15",{"date":266,"type":21},"2025-07-01",{"date":268,"type":21},"2026-08-01",{"name":180,"class":154},{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":16,"minAge":277,"maxAge":138,"enrollmentInfo":278,"targetDuration":4,"studyType":22,"phases":279,"briefSummary":280,"conditions":281,"keywords":282,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":291,"locationsCount":106},"100578497","randomized-controlled-clinical-trial-of-hyperthermia-and-hydrogen-peroxide-3-in-the-treatment-of-cutaneous-warts-100578497","NCT06812065","Randomized Controlled Clinical Trial of Hyperthermia and Hydrogen Peroxide 3% in the Treatment of Cutaneous Warts","Rrandomized Controlled Clinical Trial Named Mild Local Hyperthermia and Hydrogen Peroxide Treat Multiple Warts by Targeting a Single Lesion.","Inclusion criteria: The participants were between 16 and 65 years of age, had a clinical diagnosis of viral warts (including common warts, plantar warts, or condyloma acuminatum), and could understand and sign informed consent.\n\nExclusion criteria: presented with clinically atypical warts; had immunocompromised status or a history of HIV infection; received HPV vaccination within the past 6 months; used immunomodulators, immunosuppressants, or systemic corticosteroids within defined timeframes (4 months and 1 month, respectively); underwent local therapies (e.g., laser, cryotherapy, retinoids) on or near warts within protocol-specified intervals; had a history of cutaneous malignancies or current precancerous lesions; exhibited active dermatologic\u002Fsystemic diseases (e.g., psoriasis, eczema) or skin conditions (e.g., sunburn) potentially increasing study risks; or were deemed ineligible by investigators for other medical or logistical reasons.","16 Years",{"count":86,"type":21},[142],"Hyperthermia treatment (hyperthermia) refers to treating diseases with temperature (39-45 ° C) beyond normal body temperature,. It has been reported that local warming at 44 ° C is able to effectively mobilize the body's immunity and clear HPV infected lesions, such as condyloma acuminatum and verruca vulgaris, etc.\n\nHydrogen peroxide (H2O2) is a commonly used disinfectant for skin debridement. It has been reported that high concentration of H2O2 (45% H2O2) is effective in the treatment of warts vulgaris, however, high concentration of H2O2 will cause more local pain, itching and burning sensation. 3% hydrogen peroxide is commonly used as skin debridement disinfectant.\n\nThe purpose of the study is to evaluate the efficacy and safety of 44℃ hyperthermia combined with 3% hydrogen peroxide in treating verruca virus.",[31],[283,31,284],"hyperthermia","Hydrogen Peroxide","2025-02-02",{"date":287,"type":40},"2025-02-06",{"date":289,"type":40},"2022-12-07",{"date":44,"type":21},{"name":153,"class":154},{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":22,"phases":301,"briefSummary":302,"conditions":303,"keywords":304,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":106},"100487326","phase-2-human-papillomavirus-hpv-vaccination-vs-placebo-for-the-treatment-of-refractory-cutaneous-warts-100487326","NCT05625633","Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts","Human Papillomavirus (HPV) Vaccination for the Treatment of Refractory Cutaneous Warts: A Randomized, Placebo-Controlled, Double-Blinded Trial","Inclusion Criteria:\n\n1. Must be able to understand and provide written informed consent\n2. Age 18 or older\n3. Clinical diagnosis of cutaneous warts\n4. Must have received prior treatment for cutaneous warts (such as curettage, cryotherapy, salicylic acid, intralesional Candida antigen injection, etc.)\n\nExclusion Criteria:\n\n1. Untreated cutaneous warts\n2. Anogenital warts\n3. Oral warts\n4. Treatment for cutaneous warts in the past 4 weeks\n5. Active acute illness\n6. Immunosuppression\n7. Known hypersensitivity to HPV vaccination\n8. Subjects may not receive any other investigational treatment\n9. Pregnancy or planned pregnancy during the study period",{"count":300,"type":21},120,[25,88],"This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for the treatment of refractory cutaneous warts.",[31],[305,306,307],"Refractory cutaneous warts","Human Papillomavirus (HPV) Vaccination","HPV vaccine","2024-04-04",{"date":310,"type":40},"2024-04-05",{"date":312,"type":40},"2024-03-25",{"date":314,"type":21},"2026-12",{"name":316,"class":154},"Western Institute for Veterans Research"]